Avidity Biosciences Inc. (RNA)
30.79
-0.14 (-0.45%)
At close: Apr 25, 2025, 3:59 PM
31.58
2.57%
Pre-market: Apr 28, 2025, 04:30 AM EDT
Company Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.
It also offers Lumizyme therapy for Pompe diseases.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences Inc.
| Country | United States |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 391 |
| CEO | Sarah Boyce |
Contact Details
Address: 10578 Science Center Drive San Diego, California United States | |
| Website | https://www.aviditybiosciences.com |
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599901 |
| CUSIP Number | 05370A108 |
| ISIN Number | US05370A1088 |
| Employer ID | 46-1336960 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sarah Boyce | President, Chief Executive Officer & Director |
| John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer & Corporate Secretary |
| Michael F. MacLean CPA | Chief Financial Officer |
| Charles Calderaro III | Chief Technical Officer |
| Dr. Frank P. McCormick Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
| Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder & Independent Chairman |
| Dr. W. Michael F. Flanagan Ph.D. | Chief Scientific Officer |
| Eric B. Mosbrooker | Chief Commercial Officer |
| Prof. Mark E. Davis Ph.D. | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
| Teresa McCarthy | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 21, 2025 | 4 | Filing |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 4 | Filing |